These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Chaperoning oncogenes: Hsp90 as a target of geldanamycin. Neckers L Handb Exp Pharmacol; 2006; (172):259-77. PubMed ID: 16610363 [TBL] [Abstract][Full Text] [Related]
4. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Neckers L Trends Mol Med; 2002; 8(4 Suppl):S55-61. PubMed ID: 11927289 [TBL] [Abstract][Full Text] [Related]
5. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Tsutsumi S; Neckers L Cancer Sci; 2007 Oct; 98(10):1536-9. PubMed ID: 17645779 [TBL] [Abstract][Full Text] [Related]
6. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer. Neckers L Curr Top Med Chem; 2006; 6(11):1163-71. PubMed ID: 16842153 [TBL] [Abstract][Full Text] [Related]
7. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents. Neckers L; Neckers K Expert Opin Emerg Drugs; 2002 Oct; 7(2):277-88. PubMed ID: 15989551 [TBL] [Abstract][Full Text] [Related]
8. Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification. Neckers L Curr Med Chem; 2003 May; 10(9):733-9. PubMed ID: 12678776 [TBL] [Abstract][Full Text] [Related]
9. Heat shock protein 90: a unique chemotherapeutic target. Cullinan SB; Whitesell L Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800 [TBL] [Abstract][Full Text] [Related]
10. Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up? Isaacs JS Expert Opin Investig Drugs; 2005 Jun; 14(6):569-89. PubMed ID: 16004589 [TBL] [Abstract][Full Text] [Related]
11. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex. Stravopodis DJ; Margaritis LH; Voutsinas GE Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746 [TBL] [Abstract][Full Text] [Related]
12. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects. Garg G; Khandelwal A; Blagg BS Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001 [TBL] [Abstract][Full Text] [Related]
13. Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases. Brandt GE; Blagg BS Curr Top Med Chem; 2009; 9(15):1447-61. PubMed ID: 19860731 [TBL] [Abstract][Full Text] [Related]
14. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. Miyata Y Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661 [TBL] [Abstract][Full Text] [Related]
15. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update. Neckers L; Neckers K Expert Opin Emerg Drugs; 2005 Feb; 10(1):137-49. PubMed ID: 15757409 [TBL] [Abstract][Full Text] [Related]
17. Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors. Woodford MR; Dunn D; Miller JB; Jamal S; Neckers L; Mollapour M Adv Cancer Res; 2016; 129():31-50. PubMed ID: 26916000 [TBL] [Abstract][Full Text] [Related]
18. Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer. Haque A; Alam Q; Alam MZ; Azhar EI; Sait KH; Anfinan N; Mushtaq G; Kamal MA; Rasool M Curr Pharm Des; 2016; 22(20):2947-59. PubMed ID: 27013225 [TBL] [Abstract][Full Text] [Related]
19. Strategies for stalling malignancy: targeting cancer's addiction to Hsp90. Prodromou C Curr Top Med Chem; 2009; 9(15):1352-68. PubMed ID: 19860736 [TBL] [Abstract][Full Text] [Related]
20. X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response. Zhao Z; Zhu J; Quan H; Wang G; Li B; Zhu W; Xie C; Lou L Oncotarget; 2016 May; 7(20):29648-63. PubMed ID: 27105490 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]